Core Insights - MARA Holdings, Inc. reported a 15% month-over-month decrease in blocks won and BTC produced in April 2025, attributed to a significant increase in global hashrate and mining difficulty [3][5] - The company's energized hashrate grew by 5.5% to 57.3 EH/s, supported by a recent 50 MW expansion at its Ohio data center [3][5] - As of April 30, 2025, MARA held a total of 48,237 BTC and did not sell any BTC during the month [6] Operational Highlights - Number of Blocks Won decreased from 242 in March to 205 in April, a decline of 15% [5] - BTC Produced fell from 829 in March to 705 in April, also a 15% decrease [5] - Average BTC Produced per Day decreased from 26.8 to 23.5, a 12% decline [5] - Share of available miner rewards decreased from 5.8% to 5.1% [5] - Energized Hashrate increased from 54.3 EH/s to 57.3 EH/s, a growth of 5.5% [5] Strategic Focus - The company aims to transform into a vertically integrated digital energy and infrastructure company, enhancing operational control and cost efficiency [4][10] - Recent expansions include fully energizing 25 MW gas-to-power operations in North Dakota and Texas, which provide the lowest cost per BTC mined [4][10]

SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2025 financial results and business highlights. Dial-in information for conference participants may b ...

BURLINGTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global leader pioneering conversational AI-powered user experiences, today announced an expanded collaboration with its long-time partner and distributor, Code Factory, to introduce VoiceTopping, a new solution that will bring conversational AI to self-service kiosks in a variety of industries. The announcement marks an important step as Cerence AI begins its strategic expansion into new markets, bringing the p ...

BOCA RATON, FL, May 05, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (“DeFi Dev Corp” or the “Company”) the leading public-market vehicle for Solana (SOL) accumulation, today announced that it has entered into a definitive agreement to acquire a Solana validator business with an average delegated stake of approximately 500,000 SOL ($75.5 million). The purchase price of $3.5 million will be satisfied through a combination of $3 million in restricted DFDV stock and $500,000 in cash. Upon com ...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces that it has extended the expiry date of an aggregate of 4,752,969 outstanding warrants (the “2023 Warrants”). The 2023 Warrants were issued in connection with the clos ...

Core Insights - Firefly Neuroscience, Inc. has acquired Evoke Neuroscience, Inc., marking a significant step towards developing a proprietary foundation model of the human brain using its FDA-cleared Brain Network Analytics (BNA™) technology [1][2]. Company Overview - Firefly is an AI company focused on improving brain health outcomes for patients with neurological and mental disorders, utilizing its BNA™ technology for diagnostics and treatment monitoring [3][4]. - The company has built a comprehensive database of brain wave tests and secured patent protection over the past 15 years, now targeting pharmaceutical companies and medical practitioners for commercial use [3]. Acquisition Details - The acquisition of Evoke will enhance Firefly's assets, including a more than two-fold increase in proprietary brain scans, a three-fold increase in patents, and a ten-fold increase in commercial sites [2]. - The purchase terms include a total payment of $6 million, split 50% in cash and 50% in Firefly's common stock priced at $3.50 per share, along with a potential $500,000 earn-out for Evoke's investors based on future revenue performance [5]. Technological Synergies - The integration of Evoke's technologies is expected to create significant technological, clinical, and commercial synergies, enhancing Firefly's capabilities in brain health assessment [2]. - Firefly's BNA™ technology utilizes AI and machine learning on a proprietary database of over 17,000 patients, providing comprehensive insights into brain function and improving diagnostic accuracy for mental and cognitive disorders [4]. Market Position - Firefly possesses the largest known proprietary database of over 180,000 standardized EEG/ERP assessment records and has 27 granted patents, positioning the company strongly in the brain health technology market [5].

Nasdaq CopenhagenEuronext DublinLondon Stock Exchange Other partners Date 5 May 2025 Implementation of capital reduction As advised in the company announcement of 5 March 2025 “Minutes of the annual general meeting held on 5 March 2025”, it was decided at the bank´s annual general meeting to reduce the bank´s share capital by nom. DKK 1,315,042 by cancellation of 1,315,042 own shares. The deadline of the statutory notice to the bank’s creditors has expired with no claims being reported, and final registra ...

Highlights Binding strategic alliance with KBR (NYSE: KBR), a world-leading engineering group and global technology licensor set to supercharge Hazer’s commercialisation strategyHazer is KBR’s exclusive partner for marketing and licensing of methane pyrolysis technologyClear revenue visibility targeting multiple license deals within 6 years, materially derisking Hazer’s businessplan Capital-lite licensing model maintained; KBR A$3million work program contribution preserves Hazer’s robust funding positionStr ...

– Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATH434 for the treatment of Multiple S ...

LOUISVILLE, Ky., May 05, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. ("Creative Realities," "CRI," or the "Company") (NASDAQ: CREX), a leading provider of digital signage and media solutions, announced today that it will release its financial results for the three months ended March 31, 2025 before the market open on Wednesday, May 14, 2025. A conference call to review the results is scheduled for Wednesday, May 14, 2025, at 9:00 am Eastern Time, which will include prepared remarks and materials from ...